China SXT Pharmaceuticals Inc
NASDAQ: SXTC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-04-30
China SXT Pharmaceuticals Inc (SXTC) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for SXTC.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
SXTC historical valuation range
Where current P/E sits in SXTC's own 5Y range.
SXTC intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
SXTC valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 1.30x
Is SXTC overvalued in 2026?
China SXT Pharmaceuticals Inc (SXTC) currently trades at $2.06 per share with a market capitalization of $2,002,400.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 38/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
SXTC currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 1.3x, the market is valuing the company primarily on its revenue rather than its earnings.
Our discounted cash flow model estimates SXTC's intrinsic value at $2.61 per share, against the current market price of $2.06. This implies a margin of safety of +4.60%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.
Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: SXTC appears richly valued on our framework, with a Smart Value Score of 38/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is SXTC overvalued in 2026?
Based on a Smart Value Score of 38/100, SXTC appears overvalued. Current price exceeds what fundamentals currently justify.
What is SXTC's fair value?
Our DCF model estimates SXTC's intrinsic value at $2.61 per share, versus the current price of $2.06. This produces a margin of safety of +4.60%.
What P/E ratio does SXTC trade at?
SXTC does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.
Is SXTC a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 38/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does SXTC's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on SXTC.
What is SXTC's Smart Value Score?
SXTC's Smart Value Score is 38/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.